Once-Weekly Growth Hormone: 365 Shots a Year, or 52?

Seven Shots a Week, or One

Picture the nightly ritual in a household with a child who has growth hormone deficiency. A small subcutaneous injection, every evening, 365 times a year, for years. The child who flinches. The parent who has to be the one holding the pen. The vacation where the cooler with the medication gets left at security. Daily recombinant human growth hormone, or somatropin, has been the standard treatment since the mid-1980s, and for four decades the only real question was which daily brand to use: Genotropin, Norditropin, Humatrope, Nutropin AQ, Saizen, or Omnitrope. They are clinically interchangeable in the ways that matter.

Then, between 2021 and 2023, the U.S. Food and Drug Administration approved three long-acting growth hormones that you inject once a week. Skytrofa, the generic name lonapegsomatropin, from Ascendis Pharma, arrived first in August 2021.¹ Sogroya, or somapacitan, from Novo Nordisk, gained its pediatric approval in 2023.⁶ Ngenla, or somatrogon, from Pfizer and OPKO, followed in June 2023.⁵ All three are approved for pediatric growth hormone deficiency. The pitch writes itself: one needle a week instead of seven, fewer fights at bedtime, better adherence, happier kids.

It is a genuinely appealing story, and parts of it are true. But "more convenient" and "better medicine" are not the same claim, and the gap between them is exactly the kind of place where marketing likes to set up camp. So let's look at what the trials actually measured, what they proved, and what they conspicuously did not.

Why Growth Hormone Wanted to Be Daily in the First Place

Growth hormone is secreted by the pituitary gland in pulses, mostly at night. It travels to the liver and other tissues and triggers the release of insulin-like growth factor 1, or IGF-1, which is the molecule that actually does most of the downstream work of making bones and tissues grow. When a child cannot make enough growth hormone, you replace it. The natural rhythm is pulsatile, so the original logic of daily dosing was to roughly approximate a frequent, physiologic signal without asking families to inject several times a day.

Making a hormone last a whole week is a real pharmacological feat, and the three new drugs each solve it differently. Lonapegsomatropin is a "prodrug": ordinary growth hormone is attached to an inert carrier that slowly releases the active hormone over the week. Somapacitan is growth hormone engineered to grab onto albumin, the most abundant protein in blood, which keeps it circulating far longer than the native molecule. Somatrogon fuses growth hormone to fragments of a pregnancy hormone, which extends its half-life. Different chemistry, same goal: a flat-ish, weeklong exposure from a single shot.

That engineering creates the one biological wrinkle worth holding onto for later. Daily dosing produces a relatively even IGF-1 level. A weekly drug, by design, produces a peak in the days after the injection and a trough before the next one. The weekly average can sit comfortably in the target range while the peaks run higher than anything a child on daily therapy would see. Whether those recurring peaks matter over a childhood of treatment is the central unanswered safety question, and we'll come back to it.

Three Trials, One Yardstick: Centimeters of Height in a Year

Here is the part that deserves credit. Each weekly drug was tested against a daily comparator in a randomized, controlled Phase 3 trial in treatment-naive, prepubertal children, with the same primary endpoint: annualized height velocity, or how many centimeters of height the child gained over the first year. These are real, adequately powered trials, not the thin preclinical gruel this newsletter usually has to wade through. The catch is in the word "non-inferiority," which I'll unpack right after the numbers.

Read those three cards together and a pattern emerges that the press releases tend to blur. One weekly drug came in numerically higher, one came in a statistical tie, and one came in numerically lower than its daily comparator. What they share is not superiority. What they share is that none of them grew children worse by a meaningful margin over one year. That is a real and valuable finding. It is also a narrower finding than the marketing implies.

What "Just as Good" Actually Means

Non-inferiority is one of the most widely misunderstood concepts in medicine, and the misunderstanding is load-bearing for how these drugs are sold. A non-inferiority trial does not try to prove the new drug is better, or even equal. It tries to prove the new drug is not worse by more than a pre-agreed margin. In these trials, that margin was generous: roughly 1.8 to 2.0 cm/year of height velocity.^1,4 A weekly drug could, in principle, have grown children somewhat less than daily therapy and still "passed," as long as it stayed inside that buffer.

That is not a knock on the design. Non-inferiority is the right framework when you already have an effective treatment and you are introducing an alternative whose main advantage is convenience, not potency. Nobody expected weekly growth hormone to out-grow daily; they hoped it would roughly match it while being easier to live with. On that question, the trials delivered a clean answer.

The one place the line gets blurry is lonapegsomatropin, where the confidence interval excluded zero and the sponsor leaned into a "superiority" message. I want to be careful and fair here: a confidence interval that excludes zero is a real statistical observation, not a fabrication. But it came from a single open-label trial in which everyone knew which child was getting the shiny new weekly drug, and the pre-specified primary goal was non-inferiority, not superiority. Independent endocrinologists published letters cautioning against over-reading it.¹ "Numerically higher in one unblinded trial" is a reasonable thing to mention and an unreasonable thing to build a brand promise on.

The Strongest Case for Weekly Has Nothing to Do With Centimeters

If the height-velocity numbers are roughly a wash, why bother? Because the real argument for weekly dosing was never that it grows children more in a controlled trial. It is that in the messy real world, where adherence is imperfect, fewer injections may mean the medicine actually gets taken.

The adherence problem with daily growth hormone is well documented and genuinely large. Across studies, non-adherence estimates run anywhere from a handful of percent to most of a cohort, depending on how you define it; using the common threshold of more than one missed dose per week, the figure lands somewhere around 36 to 49 percent, with roughly a quarter of children missing more than two injections a week.^11,12 Older children miss more than younger ones, which is its own quiet tragedy, because adherence tends to fall apart right as the growth window starts closing.

And missed doses are not free. A real-world study of 201 children found that good adherence translated into roughly 1.8 cm more height over a single year compared with non-adherent peers, with the children missing the most doses showing the smallest gains.¹³ That is on the same order as the entire treatment difference the trials were arguing about. In other words, the variable that may matter most for how tall a child actually gets is not which molecule you chose, but whether the shots got given.

On burden, the data favor weekly clearly. A randomized crossover study of 87 patients comparing once-weekly somatrogon with daily somatropin found a far lower "life interference" score on weekly dosing — 8.63 versus 24.13 on the instrument's scale — and patients preferred the weekly regimen.⁹ A separate quality-of-life analysis pointed the same direction.¹⁰ These are validated patient-reported measures, and the effect sizes are not subtle.

So here is the honest synthesis. Better adherence is the single most plausible route by which weekly growth hormone could eventually beat daily in the real world. But notice the trap: the pivotal trials enrolled motivated, closely monitored families, where the daily arm took its shots faithfully. That is exactly why those trials could only show non-inferiority. The adherence advantage is inferred and biologically sensible, but it has not yet been demonstrated in an outcomes trial. We are reasoning that fewer shots will be taken more reliably. We have not yet watched it produce taller adults.

What We Don't Know Yet, and Can't Pretend To

These drugs are two to five years old. Growth hormone therapy in a child can run for a decade. That mismatch is the whole ballgame for the open questions, and there are four worth naming plainly.

None of these is a reason to panic, and none is evidence of harm. They are honest blanks on the form. The short-term safety data across all three trials looked broadly similar to daily growth hormone, with mostly mild adverse events and no new alarms in the first year.^1,4,6 The point is narrower and more disciplined: a 2021-to-2023 approval cannot, by the simple passage of time, have a 2035 safety record. Anyone telling you these are "proven safe for the long haul" is describing a future that has not happened yet.

Dr. Cole's Read